All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results Terminated | 2004-004403-37 | Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zur S... | 2011-03-31 | due-trials |
Reported results Terminated | 2005-001762-13 | Energy metabolism of critically ill children treated with lipid emulsion and carnitine | 2005-07-07 | due-trials |
Reported results | 2005-003201-81 | GACHE: German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis. A multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial. | 2012-12-31 | due-trials |
Ongoing | 2005-003911-63 | Combined Radiochemotherapy with Erbitux (Cetuximab) plus Temozolomide in the primary therapy of Glioblastoma Multiforme (GBM) - Phase I/II Trial | not-yet-due | |
Reported results Terminated | 2006-001146-13 | "Investigation of Caspofungin Plasma Concentration and Pharmacokinetic for the Improvement of the Antifungal Therapy in Patients of Surgical Intensive Care Unit" | 2006-08-14 | due-trials |
Reported results | 2006-001212-72 | Therapie des nodalen Follikulären Non-Hodgkin-Lymphoms (WHO Grad I/II) im klinischen Stadium I / II mittels involved-field Bestrahlung in Kombination mit Rituximab (Mabthera Involved-field Radiotherap... | 2013-04-10 | due-trials |
Reported results Terminated | 2006-001732-53 | Eine multizentrische, randomisierte, kontrollierte Studie zur Untersuchung von Adalimumab bei der Behandlung verschiedener Formen von refraktärer Uveitis im Vergleich zur Standardtherapie Randomized ... | 2013-01-08 | due-trials |
Reported results | 2006-002056-14 | Akute Cholezystitis – Frühe laparoskopische Operation versus antibiotischer Therapie mit elektiver Cholezystektomie im Intervall (ACDC-Studie) (Acute cholecystitis – early laparoscopic surgery versus ... | 2010-11-28 | due-trials |
Reported results | 2006-002338-39 | Pharmakokinetik von Linezolid bei Dialyse (pharmacokinetics of linezolid under dialysis) | 2008-04-13 | due-trials |
Reported results | 2006-005308-15 | Pilot study of the safety and tolerance of preoperative melatonin application in patients undergoing major liver resection. | 2009-03-30 | due-trials |
Reported results Terminated | 2006-006573-24 | Prospective influence of bedtime insulin glargine on mobilization and function of endothelial progenitor cells in patients with type 2 diabetes: a partially double-blind, randomized, three-arm unicent... | 2009-06-17 | due-trials |
Reported results | 2007-002755-16 | Pharmakokinetik von Posaconazol verabreicht über Magensonde - POLICE-Studie (POsaconazoLe via gastrIC tubE) | 2009-08-07 | due-trials |
Reported results Terminated | 2007-004535-33 | Phase II study on curative resectability of not optimally resectable liver and/or lung metastases from colorectal carcinoma (CRC) under intensified chemotherapy (FLOFOXIRI/Bevacizumab). | 2011-03-16 | due-trials |
Exempt, with results | 2007-005537-11 | Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia | 2017-03-24 | not-yet-due |
Not reported | 2008-001090-15 | Randomized, double-blind Phase II study of Docetaxel + Sorafenib (Nexavar®) versus Docetaxel + Placebo in First-Line treatment of patients with HER2-negative, metastatic breast cancer. | 2013-12-31 | due-trials |
Reported results | 2008-001669-27 | A phase-III study on the value of allogeneic stem cell transplantation in poor-risk chronic lymphocytic leukemia by the German CLL Study Group (GCLLSG) and the German Cooperative Transplant Study Grou... | 2011-07-20 | due-trials |
Reported results Terminated | 2008-002269-29 | A prospective, randomized, double-blind, multicenter, Phase III clinical study on transarterial chemoembolisation (TACE) combined with Sorafenib vs. TACE plus placebo in patients with hepatocellular c... | 2013-02-18 | due-trials |
Reported results Terminated | 2008-002667-13 | A single-center controlled pilot study to investigate pre- and perioperative therapy with Sorafenib (Nexavar®) in patients who are candidates for a curative surgery of renal cell cancer (PREST = preop... | 2013-09-10 | due-trials |
Not reported | 2008-003174-18 | Open-labeled, randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated car... | 2020-01-31 | due-trials |
Reported results Terminated | 2008-004696-22 | An Open Label Randomized Multicentre Phase IIIb Trial Comparing Parenteral Substitution versus Best Supportive Nutritional Care in Subjects with Pancreatic Adenocarcinoma Receiving 5-FU plus Oxaliplat... | 2014-08-21 | due-trials |
Listed as ongoing, but also has a completion date and reported results | 2008-005653-37 | Multicenter, prospective randomized trial on the use of prothrombin complex and fresh frozen plasma in patients with intracerebral hemorrhage related to vitamin K antagonists (VKA) | 2015-02-06 | bad-data |
Reported results | 2008-006871-60 | Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma | 2013-06-30 | due-trials |
Reported results | 2008-008513-19 | Phase II Studie zur Wirksamkeit und Verträglichkeit von Vorinostat bei Patienten mit fortgeschrittenen, metastasierten Weichteilsarkomen. English title: A Phase II Study to Investigate the Efficacy an... | 2013-09-13 | due-trials |
Reported results Terminated | 2009-009277-10 | Neoadjuvant Radiochemotherapy Combined with Panitumumab in Locally Advanced KRAS wild-type Rectal Cancer | 2012-08-16 | due-trials |
Reported results | 2009-009894-88 | Lapatinib versus Lapatinib with Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A randomized phase II trial | 2013-04-24 | due-trials |
Reported results | 2009-013279-23 | In vivo response monitoring of treatment with the EGFR-monoclonal-antibody Cetuximab in metastatic colorectal cancer – a single center phase II study | 2016-12-21 | due-trials |
Reported results | 2009-013856-61 | A phase III national, multicentre, randomized open-label study with Lenalidomide/Dexamethasone versus Lenalidomide/Dexamethasone and autologous stem cell transplantation followed by Lenalidomide maint... | 2017-06-30 | due-trials |
Reported results | 2009-016631-35 | Phase II Trial of Ipilimumab in Patients with advanced melanoma and spontaneous preexisting immune response to NY-ESO-1 | 2016-06-03 | due-trials |
Exempt, with results Terminated | 2009-017328-25 | A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer | 2015-10-15 | not-yet-due |
Reported results | 2010-019173-16 | Randomised phase III trial for previously untreated multiple myeloma to evaluate two regimens of bortezomib based induction therapy and lenalidomide consolidation followed by lenalidomide maintenance ... | 2017-03-11 | due-trials |
Exempt, with results Terminated | 2010-022425-15 | ACCEPT - (ACC, Erbitux® and particle therapy) - Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost (Phase I/II feasibility study) | not-yet-due | |
Exempt | 2011-000921-61 | A phase I/II, randomized, open-label, multi-centre study of BIBF1120 + reirradiation (R-RT) versus reirradiation in the treatment of patients with first or second progression of glioblastoma | 2017-09-30 | not-yet-due |
Reported results | 2011-001491-20 | A phase II trial to evaluate the safety, feasibility and efficacy of a salvage therapy consisting of the mTOR inhibitor Temsirolimus (Torisel™) added to the standard therapy of Rituximab and DHAP for ... | 2018-11-01 | due-trials |
Reported results | 2011-003273-28 | Treatment of patients with metastatic melanoma (AJCC stage IV or III unresectable) with the PDE-inhibitor Tadalafil: A Pilot Trial for “Proof of Principle” Pilot-Studie zur Behandlung von Patiente... | 2015-03-25 | due-trials |
Not reported | 2012-001650-26 | A randomised, placebo-controlled, double-blind, monocentre study on the application of physostigminsalicylate (Anticholium®) as adjunctive measure in perioperative sepsis/septic shock Eine randomi... | 2017-02-18 | due-trials |
Reported results Terminated | 2012-003528-19 | STEM CELL TRANSPLANTATION FOR ERADICATION OF MINIMAL PANCREATIC CANCER PERSISTING AFTER SURGICAL EXCISION | 2016-06-13 | due-trials |
Reported results | 2012-003609-80 | European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits. | 2017-12-18 | due-trials |
Reported results Terminated | 2013-000211-24 | A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuvant ... | 2014-12-10 | due-trials |
Reported results | 2013-005485-19 | Bendamustine, Prednisone and Velcade® for first-line treatment of patients with symptomatic multiple myeloma not eligible for high-dose chemotherapy followed by autologous stem cell transplantation (B... | 2019-08-01 | due-trials |
Ongoing | 2014-001991-76 | Initial treatment of idiopathic nephrotic syndrome in children with mycophenolate mofetil vs. prednisone: A randomized, controlled, multicenter study | not-yet-due | |
Reported results | 2014-003079-40 | A randomized phase III trial on the effect of elotuzumab in VRD induction /consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma Randomisierte Phase III-Studie für Pat... | 2021-06-24 | due-trials |
Exempt | 2015-002752-27 | Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation: NCT Neuro Master M... | 2023-03-22 | not-yet-due |
Ongoing | 2015-003920-30 | Phase-II study on the value of post-transplant Cyclophosphamide after Thiotepa-based haplo-identical stem-cell transplantation for relapsed-refractory lymphoma Eine Studie zum Stellenwert von Cyc... | not-yet-due | |
Completed, report not yet due | 2016-002059-89 | Therapy of Nodal Follicular Non-Hodgkin Lymphoma (WHO grade 1/2) in Clinical Stage I/II using Response Adapted Involved Site Radiotherapy in Combination with Gazyvaro | 2024-04-14 | not-yet-due |
Completed, but no date | 2016-004660-19 | CDK4/6 inhibition in locally advanced/metastatic chordoma | bad-data | |
Other | 2016-004786-80 | A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis. Phase IIa, ra... | not-yet-due | |
Exempt | 2016-004808-60 | Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial Beha... | not-yet-due | |
Completed, report not yet due | 2017-001755-31 | Randomized Phase-II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies Randomisier... | 2023-12-19 | not-yet-due |
Other | 2017-004768-37 | A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) induction and lenalidomide maintenance in patients with newly diagno... | not-yet-due | |
Not reported | 2017-005158-12 | TEAM-Trial: Targeting Epigenetic therapy resistance in AML with Bortezomib: A multi-centre matched threshold crossing phase II approach TEAM-Studie: Überwindung der epigenetischen Chemotherapie-Res... | 2023-03-13 | due-trials |
Reported results Terminated | 2018-000112-21 | Prospective Window of opportunity trial 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer | 2020-01-17 | due-trials |
Exempt | 2018-000127-14 | INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies | not-yet-due | |
Reported results Terminated | 2018-000415-25 | PANCREATIC RESECTION WITH PERIOPERATIVE OFF-LABEL STUDY OF PROPRANOLOL AND ETODOLAC – A PHASE II RANDOMIZED TRIAL PROSPER Studie – Randomisierte, doppelt verblindete, Placebo-kontrollierte, Phase I... | 2021-07-09 | due-trials |
Reported results Terminated | 2018-002606-31 | Sublingual versus intravenous Fentanyl in patients with acute trauma - a randomized, double-blind, double-dummy study to demonstrate non-inferiority TraumaPACT | 2020-04-21 | due-trials |
Reported results Terminated | 2018-002675-17 | Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD | 2022-09-12 | due-trials |
Exempt Terminated | 2018-002979-17 | Use of doxapram as a new antiarrhythmic drug for a specific therapy of atrial fibrillation Einsatz von Doxapram als neues Antiarrhythmikum für eine spezifische Vorhofflimmertherapie | 2023-10-25 | not-yet-due |
Completed, but no date, and reported results Terminated | 2018-004562-33 | A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or ref... | bad-data | |
Ongoing | 2018-005027-16 | Improvement of functional Outcome for patients with newly diagnosed grade 2 or 3 glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial IMPROVE CODEL: Verbesserung des funktionellen Er... | not-yet-due | |
Exempt | 2019-001759-38 | Pharmacokinetics of a microdosed cocktail containing rivaroxaban, apixaban and edoxaban in children with congenital heart defects Pharmakokinetik eines mikrodosierten Cocktails bestehend aus Rivaro... | not-yet-due | |
Completed, report not yet due Terminated | 2019-002461-35 | Monocenter, randomized, controlled, open-label, phase-II clinical trial of PREoperative endoscopic injection of BOTulinum toxin in the sphincter of Oddi to reduce postoperative pancreatic fistula afte... | 2023-10-11 | not-yet-due |
Reported results | 2019-003913-32 | Randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare intensive postremission therapy double blinded with or without gla... | 2022-09-09 | due-trials |
Ongoing | 2020-000388-21 | Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB (T3N2 only) non-squamous Non-Small Cell Lun... | not-yet-due | |
Reported results | 2020-001632-10 | A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Dise... | 2022-04-05 | due-trials |
Ongoing | 2020-004906-79 | An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy... | not-yet-due | |
Ongoing | 2020-006001-35 | Randomized controlled trial of PREoperative injection of BOTulinum toxin into the sphincter of Oddi to reduce bile leakage after hepatic resection PREBOT-II Randomisiert-kontrollierte Studie zur ... | not-yet-due | |
Other | 2021-000362-15 | Early Stage Follicular Lymphoma and Radiotherapy PLUS anti-CD20 Antibody Therapie des nodalen Follikulären Lymphoms im frühen Stadium: Radiotherapie plus anti-CD20 Antikörper | not-yet-due | |
Ongoing | 2022-000996-38 | A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients w... | not-yet-due | |
Ongoing | 2022-001186-12 | A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab- and Talquetamab-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma Phase-2-Studie z... | not-yet-due |